Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc
(NQ:
CMND
)
1.310
-0.070 (-5.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clearmind Medicine Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why BSQUARE Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
October 12, 2023
Gainers OpGen, Inc. (NASDAQ: OPGN) shares rose 432% to $1.79 in pre-market trading. Opgen said on Oct. 6, unit Curetis GMBH received payment of 750,000 euros related to the sale of certain Unyvero A50...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
October 12, 2023
Pre-market stock movers are a hot topic among traders on Thursday and we're offering all of the latest coverage this morning!
Via
InvestorPlace
Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th
October 05, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
October 11, 2023
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in...
Via
Benzinga
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND)
September 19, 2023
Via
ACCESSWIRE
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
September 20, 2023
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
September 18, 2023
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
Via
Benzinga
Exposures
Product Safety
Clearmind Medicine Closes US$2.25 Million Public Offering
September 18, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind's $2.25M Public Offering
September 15, 2023
Beckley Waves: $3.3 Million Round To Expand Safe & Legal Access To Psychedelic Therapies
Via
Benzinga
Nasdaq Surges 100 Points; First Wave BioPharma Shares Spike Higher
September 14, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.93% to 34,898.47 while the NASDAQ rose 0.75% to 13,917.44....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
September 14, 2023
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi.
Via
Benzinga
Crude Oil Rises Sharply; BIOLASE Shares Plunge
September 14, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.61% to 34,784.94 while the NASDAQ rose 0.71% to 13,911.78. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Clearmind Medicine Stock Is Getting Hammered Today
September 14, 2023
Clearmind Medicine Inc (NASDAQ: CMND) shares are trading lower by 53% to $0.18 Thursday morning after the company announced pricing of a $2.25 million public offering. The offering is expected to close...
Via
Benzinga
Dow Jumps Over 200 Points; US Producer Prices Rise In August
September 14, 2023
U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.71% to 34,820.58 while the NASDAQ rose 0.27% to 13,849.49. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering
September 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Why Novo Integrated Sciences Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
September 14, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 43.3% to $1.29 in pre-market trading.
Via
Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Nasdaq Grants SpiSparc, Ltd. Extension To Maintain Listing: +600% Bid Price Surge Needed
September 07, 2023
Specialty clinical-stage biopharma company SciSparc Ltd. (NASDAQ: SPRC) has received a Nasdaq notice granting the company an additional 180-day compliance period until March 4 to regain compliance with...
Via
Benzinga
Johns Hopkins Will Work With Clearmind On Alcohol Addiction Research Program
September 06, 2023
Israeli psychedelics biotech Clearmind Medicine (NASDAQ: CMND) has inked a research agreement with Johns Hopkins University School of Medicine (JHU) to conduct the first-in-human Phase I/IIa clinical...
Via
Benzinga
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
September 06, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
August 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
August 01, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
August 01, 2023
From
SciSparc Ltd
Via
GlobeNewswire
EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio
August 01, 2023
Clearmind Medicine Inc (NASDAQ: CMND) has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of...
Via
Benzinga
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
July 17, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
July 11, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome
June 16, 2023
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:CMND) (FSE:CWY) announced that as part of the company's ongoing collaboration with SciSparc Ltd.
Via
Benzinga
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
June 09, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.